Ascendis Pharma Gets Orphan Drug Exclusivity for Hormone Treatment Yorvipath in U.S.

Ascendis Pharma receives 7 years of orphan drug exclusivity from the FDA for Yorvipath, a treatment for hypoparathyroidism.